CRISPR-Edited Cells for Sensitive Complement-Mediated Lysis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting transplant donor organ-reactive antibodies in human patients are limited in sensitivity, particularly in identifying low levels of antibodies that can lead to xenograft rejection.
Innovation Solution
The method involves genetically modifying cells derived from candidate animal transplant donor organs to reduce the expression of complement inhibitors, such as CD46, CD55, and CD59, using CRISPR Cas9 technology. These modified cells are then contacted with a sample of serum from a human patient, and lysis of the cells is detected to indicate the presence of donor organ-reactive antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods are used to detect transplant donor organ-reactive antibodies, then the detection process is simple, but the sensitivity is limited and low levels of antibodies cannot be detected
Solution Approach 1:
The patent modifies the detectability parameter of cell surfaces by reducing complement inhibitor expression. This creates a parameter change that enhances antibody detection sensitivity, allowing low-level antibodies to be detected through increased lysis signals in the modified cell population.
Solution Approach 2:
The patent uses complement inhibitors as intermediary molecules that mediate between antibodies and cell lysis. By reducing complement inhibitor expression on cell surfaces, the intermediary mechanism is optimized to amplify the detection signal, enabling sensitive detection of low-level donor organ-reactive antibodies.
2Measurement precision
If cells with high complement inhibitor expression are used, then cell stability is maintained, but antibody detection sensitivity is reduced
Solution Approach 1:
The patent strategically changes the complement inhibitor expression parameter on cell surfaces to an optimized level. This parameter modification enhances antibody detection sensitivity while maintaining sufficient cell stability for the detection assay, resolving the contradiction between sensitivity and stability.
Solution Approach 2:
The patent applies partial reduction of complement inhibitor expression rather than complete elimination. This partial action approach maintains enough cell stability and protective functions while sufficiently enhancing antibody detection sensitivity, achieving an optimal balance between the two competing requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the sensitivity of detecting transplant donor organ-reactive antibodies, allowing for the identification of lower antibody levels that may not be detectable with traditional methods, thereby improving the assessment of xenograft compatibility.
Implementation Method 1
detecting lysis of the genetically modified population of cells, wherein lysis indicates if the patient desiring to receive the transplant donor organ expresses donor organ-reactive antibodies
Data Source
Figure 1A
Figure 1B~1C
Figure 2A
AI summary
A method is provided for increasing the sensitivity of the complement-dependent cellular cytoxicity analysis that establishes whether a potential transplant recipient patient expresses donor organ-reactive antibodies that would reduce or prevent acceptance of the donor organ by a recipient. At least one gene encoding a complement inhibitor is inactivated in cells derived from a candidate transplant organ. Such modified cells, because they no longer produce at least one complement inhibitor, when placed in a serum sample from a potential transplant recipient, do not reduce the effective activity of serum complement. A lower level of recipient patient serum antibodies becomes effective in inducing detectable lysis of the donor cells.